The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain

Liepe, Knut; Runge, Roswitha; Kotzerke, Jörg

doi:10.1007/s00432-004-0625-0

Cited by 66 publications

(41 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Poor general condition and considerable cachexia might also be direct causes of patient disqualification from the treatment. The first pain symptoms occur approximately after 7-14 days following dose administration and can be observed for as long as a year [43][44][45][46].…”

Section: Patient General Condition and Life Expectancymentioning

confidence: 99%

See 1 more Smart Citation

Radioisotope therapy of bone metastases

Bączyk¹

2011

Nucl Med Rev Cent East Eur.

View full text Add to dashboard Cite

IntroductionDue to constantly increasing neoplastic disease incidence, bone metastases are becoming a more and more serious issue in oncology. As regards the most common tumours, half of them are connected with a high probability of developing metastases to the skeletal system. Bones, next to lungs and liver, are among the top three sites of distant metastases localization. Neoplasms that give metastases to the skeletal system are most frequently cancers of the prostate, breast, kidneys, lungs, and thyroid (Table I). Osteoblasts have an approximate life time of 3 months and come from mesenchymoma multipotential matrix cells. They produce type I collagen and proteoglycans that form the organic intracellular structure of the bone which is further calcified. Osteoblasts are also responsible for synthesis of osteonectin, osteopontin, osteocalcin, and various types of proteinase [3,4].

show abstract

Section: Patient General Condition and Life Expectancymentioning

confidence: 99%

“…As regards isotope therapy patients, no clear statistical data regarding lengthening of life can be found. However, these patients report improved life quality, and a lower number of both pathologic fractures and clinical circumstances requiring hospitalization is observed [45,[61][62][63]. …”

Section: Economic Aspect Of Radioisotope Therapymentioning

confidence: 99%

Radioisotope therapy of bone metastases

Bączyk¹

2011

Nucl Med Rev Cent East Eur.

View full text Add to dashboard Cite

show abstract

“…Bone metastases are a frequent complication of cancer, occurring in up 70% of patients suffering from advanced breast or prostate cancer 1 . Bone metastases patients often present with severe bone pain, especially in the advanced stage of disease 1,2 .…”

Section: Introductionmentioning

confidence: 99%

“…Bone metastases patients often present with severe bone pain, especially in the advanced stage of disease 1,2 . The major pain mechanism of small metastases appears to be the stimulation of nerve endings in the endosteum by a variety of chemical mediators.…”

Section: Introductionmentioning

confidence: 99%

“…The resulting bone pain interferes with the patient's quality of life and requires effective treatment. Unfortunately, various non-radiotherapeutic modalities such as analgesics, hormone therapy, orchidectomy, cytostatic and cytotoxic drugs, bisphosphonates, and surgery are not effective in all cases, especially in the late stage of the disease 1,2 . Systemic radionuclide therapy using boneseeking radiopharmaceuticals is considered a valuable and effective method for treating patients with widespread skeletal metastases and increased bone turnover, especially in patients with bone metastases from prostate and breast cancer 3,4,5 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biodistribution of samarium-153-EDTMP in rats treated with docetaxel

et al. 2009

View full text Add to dashboard Cite

Purpose: Many patients with metastatic bone disease have to use radiopharmaceuticals associated with chemotherapy to relieve bone pain. The aim of this study was to assess the influence of docetaxel on the biodistribution of samarium-153-EDTMP in bones and other organs of rats. Methods: Wistar male rats were randomly allocated into 2 groups of 6 rats each. The DS (docetaxel/samarium) group received docetaxel (15 mg/kg) intraperitoneally in two cycles 11 days apart. The S (samarium/control) group rats were not treated with docetaxel. Nine days after chemotherapy, all the rats were injected with 0.1ml of samarium-153-EDTMP via orbital plexus (25µCi). After 2 hours, the animals were killed and samples of the brain, thyroid, lung, heart, stomach, colon, liver, kidney and both femurs were removed. The percentage radioactivity of each sample (% ATI/g) was determined in an automatic gamma-counter (Wizard-1470, Perkin-Elmer, Finland). Results: On the 9 th day after the administration of the 2 nd chemotherapy cycle, the rats had a significant weight loss (314.50±22.09g) compared (p<0.5) to pre-treatment weight (353.66± 22.8). The % ATI/g in the samples of rats treated with samarium-153-EDTMP had a significant reduction in the right femur, left femur, kidney, liver and lungs of animals treated with docetaxel, compared to the control rats. Conclusion: The combination of docetaxel and samarium-153-EDTMP was associated with a lower response rate in the biodistribution of the radiopharmaceutical to targeted tissues. Further investigation into the impact of docetaxel on biodistribution of samarium-153-EDTMP would complement the findings of this study. Key words: Taxoids. Samarium. Biological Availability. Drug Therapy. Rats. RESUMOObjetivo: Muitos pacientes com metástases ósseas são tratados com radiofármacos associados com quimioterapia para alívio da dor óssea. O objetivo do trabalho foi estudar a influência do docetaxel na biodistribuição do EDTMP-153-samário nos ossos e outros órgãos de ratos. Métodos: Ratos Wistar foram aleatoriamente alocados em 2 grupos de 6 animais cada. O grupo DS (docetaxel/samário) recebeu docetaxel (15 mg/kg) intraperitoneal em dois ciclos com 11 dias de intervalo. Os ratos do grupo S (samário/controle) não foram tratados com docetaxel. Nove dias após a quimioterapia, todos os animais receberam 0,1ml de EDTMP-153-samário via plexo orbital (25µCi). Após 2 horas, os animais foram mortos e feitas biópsias de cérebro, tireóide, pulmão, coração, estômago, cólon, fígado, rim e fêmures. O percentual de radioatividade por grama (%ATI/g) de tecido de cada biópsia foi determinado em contador gama automático (Wizard-1470, Perkin-Elmer, Finland). Resultados: No 9º após 2º ciclo de docetaxel os ratos tiveram perda de peso significante, passando de 353,66± 22,8g (controle/pré-tratamento) para 314,50±22,09g (p<0,5). Os % ATI/g nos órgãos dos ratos tratados com EDTMP-153-samário e docataxel tiveram redução significante nos fêmures direito e esquerdo, rim, fígado e pulmão, quando comparados com os não trata...

show abstract